Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renzapride in Women With Constipation-Predominant IBS
NCT00268879Phase 3Completed
- Sponsor
- Alizyme
- Start
- Dec 2005
- Primary completion
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of renzapride in irritable bowel syndrome (IBS) (3 arms), sponsored by Alizyme. Primary endpoint: Number of months a patient is a Responder for overall relief of IBS symptoms at 12 weeks. Started Dec 2005; status: completed.
02
Drugs
renzapride
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT00268879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00268879.